[Standard Cancer Therapy Are Established by the Investigator-Initiated Post-Marketing Clinical Trials, Not by the Indication-Directed Clinical Trials].

التفاصيل البيبلوغرافية
العنوان:	[Standard Cancer Therapy Are Established by the Investigator-Initiated Post-Marketing Clinical Trials, Not by the Indication-Directed Clinical Trials].
المؤلفون:	Shimada Y; Dept. of Clinical Oncology, Kochi Health Sciences Center.
المصدر:	Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2016 Apr; Vol. 43 (4), pp. 473-5.
نوع المنشور:	English Abstract; Journal Article
اللغة:	Japanese
بيانات الدورية:	Publisher: Gan To Kagaku Ryohosha Country of Publication: Japan NLM ID: 7810034 Publication Model: Print Cited Medium: Print ISSN: 0385-0684 (Print) Linking ISSN: 03850684 NLM ISO Abbreviation: Gan To Kagaku Ryoho Subsets: MEDLINE
أسماء مطبوعة:	Publication: Tokyo : Gan To Kagaku Ryohosha Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]-
مواضيع طبية MeSH:	Clinical Trials as Topic, Antineoplastic Agents/therapeutic use , Neoplasms/*drug therapy, Biomedical Research ; Humans ; Marketing of Health Services ; Practice Guidelines as Topic/standards
مستخلص:	The financial supports for investigator-initiated post-marketing clinical trial in clinical oncology are reduced after scandals related to the other fields of clinical trials in Japan. These clinical trials are the essential final steps of clinical development in newer cancer therapy, which should be conducted in the investigator-initiated clinical trial groups with well-organized infrastructure and continuous financial supports. The present problems are discussed and summarized. Future perspectives with the national viewpoints needed to be included the idea of "health technology assessment".
المشرفين على المادة:	0 (Antineoplastic Agents)
تواريخ الأحداث:	Date Created: 20160526 Date Completed: 20160613 Latest Revision: 20160525
رمز التحديث:	20231215
PMID:	27220797
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	0385-0684